Cardiol Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was CAD 7.09 million compared to CAD 8.95 million a year ago. Basic loss per share from continuing operations was CAD 0.11 compared to CAD 0.14 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.02 CAD | +0.33% | +10.22% | +174.55% |
05:31pm | Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure | MT |
04-22 | HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+174.55% | 150M | |
+29.90% | 48.16B | |
-0.95% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.46% | 25.59B | |
-22.93% | 18.96B | |
+8.26% | 12.92B | |
+28.92% | 12.03B | |
-2.14% | 11.77B |
- Stock Market
- Equities
- CRDL Stock
- News Cardiol Therapeutics Inc.
- Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023